JP2024522092A - Ｆｃ受容体に対する親和性の増強および熱安定性の改善を伴うＦｃバリアント - Google Patents

Ｆｃ受容体に対する親和性の増強および熱安定性の改善を伴うＦｃバリアント Download PDF

Info

Publication number
JP2024522092A
JP2024522092A JP2023572758A JP2023572758A JP2024522092A JP 2024522092 A JP2024522092 A JP 2024522092A JP 2023572758 A JP2023572758 A JP 2023572758A JP 2023572758 A JP2023572758 A JP 2023572758A JP 2024522092 A JP2024522092 A JP 2024522092A
Authority
JP
Japan
Prior art keywords
amino acid
polypeptide
effector
domain
acid position
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522092A5 (enExample
Inventor
ヨーヘン・ベニンガ
ベアトリス・カメロン
インゴ・フォッケン
サーガル・カトゥリア
クリスティアン・ランゲ
アレッサンドロ・マーシエロ
サングヘー・パーク
ボードー・ティルマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2024522092A publication Critical patent/JP2024522092A/ja
Publication of JP2024522092A5 publication Critical patent/JP2024522092A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2023572758A 2021-05-27 2022-05-27 Ｆｃ受容体に対する親和性の増強および熱安定性の改善を伴うＦｃバリアント Pending JP2024522092A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163193665P 2021-05-27 2021-05-27
US63/193,665 2021-05-27
EP21315127.7 2021-07-15
EP21315127 2021-07-15
PCT/IB2022/055019 WO2022249146A1 (en) 2021-05-27 2022-05-27 Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY

Publications (2)

Publication Number Publication Date
JP2024522092A true JP2024522092A (ja) 2024-06-11
JP2024522092A5 JP2024522092A5 (enExample) 2025-06-03

Family

ID=82358573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572758A Pending JP2024522092A (ja) 2021-05-27 2022-05-27 Ｆｃ受容体に対する親和性の増強および熱安定性の改善を伴うＦｃバリアント

Country Status (12)

Country Link
US (2) US12297273B2 (enExample)
EP (1) EP4347640A1 (enExample)
JP (1) JP2024522092A (enExample)
KR (1) KR20240015093A (enExample)
AU (1) AU2022282666A1 (enExample)
BR (1) BR112023022584A2 (enExample)
CA (1) CA3216005A1 (enExample)
CO (1) CO2023016432A2 (enExample)
IL (1) IL308733A (enExample)
MX (1) MX2023014100A (enExample)
TW (1) TW202306584A (enExample)
WO (1) WO2022249146A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR133427A1 (es) 2023-07-31 2025-09-24 Sanofi Sa Anticuerpos anti-gprc5d y composiciones

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017184723A (ja) * 2016-02-03 2017-10-12 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト
JP2021510535A (ja) * 2018-03-29 2021-04-30 ハミングバード・バイオサイエンス・ホールディングス・プライベート・リミテッド Ｈｅｒ３抗原結合性分子

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7312181B2 (en) 2005-04-08 2007-12-25 Cropsolution, Inc. Acylated thiosemicarbazides as herbicides
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
MX2012004029A (es) * 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2013138643A1 (en) * 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Soluble engineered monomeric fc
CA2871934C (en) 2012-04-30 2023-06-13 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
CN105102618B (zh) 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
AR103488A1 (es) 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
AR108963A1 (es) 2016-04-13 2018-10-17 Merial Inc Dispositivo de inyección con mecanismo de accionamiento para administrar múltiples formulaciones líquidas, tales como vacunas
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
CN108218998A (zh) * 2017-12-31 2018-06-29 武汉班科生物技术股份有限公司 一种突变型人源IgG的Fc片段及其制备方法与应用
BR112020015006A2 (pt) 2018-01-26 2020-12-29 Genzyme Corporation Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada
JP7792330B2 (ja) * 2019-09-03 2025-12-25 アムジエン・インコーポレーテツド Ｉｌ－２２の経口、直腸内、又は他の消化管関連の組成物及びそれを使用する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017184723A (ja) * 2016-02-03 2017-10-12 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト
JP2021510535A (ja) * 2018-03-29 2021-04-30 ハミングバード・バイオサイエンス・ホールディングス・プライベート・リミテッド Ｈｅｒ３抗原結合性分子

Also Published As

Publication number Publication date
US12297273B2 (en) 2025-05-13
US20250376526A1 (en) 2025-12-11
AU2022282666A1 (en) 2024-01-18
EP4347640A1 (en) 2024-04-10
TW202306584A (zh) 2023-02-16
WO2022249146A1 (en) 2022-12-01
KR20240015093A (ko) 2024-02-02
BR112023022584A2 (pt) 2024-01-09
MX2023014100A (es) 2023-12-11
US20230077531A1 (en) 2023-03-16
IL308733A (en) 2024-01-01
CA3216005A1 (en) 2022-12-01
CO2023016432A2 (es) 2023-12-11

Similar Documents

Publication Publication Date Title
RU2729467C2 (ru) Модифицированные антигенсвязывающие полипептидные конструкции и их применение
JP7178342B2 (ja) アゴニズム及びエフェクター機能が増強した改変抗体、及び他のＦｃドメイン含有分子
JP7399880B2 (ja) ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体
JP6224739B2 (ja) 抗ｌａｇ−３結合タンパク質
JP6675017B2 (ja) コントースボディ−単鎖標的結合物質
KR20210094588A (ko) Cd3에 결합하는 항체
JP2025098167A (ja) Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
KR102669686B1 (ko) 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도
WO2011084714A2 (en) STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
EP4155318A1 (en) Bispecific antibody and use thereof
JP2025542239A (ja) 自己免疫疾患の治療
JP2026513915A (ja) ヒンジが修飾された二重特異性抗体
US20250376526A1 (en) Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
WO2025255435A2 (en) Antigen-binding proteins against serum albumin and uses thereof
WO2024153068A1 (en) Anti-pdl1 single domain antibody, fusion protein and use thereof
KR101804988B1 (ko) 신규 항-tfpi 항체 및 이를 포함하는 조성물
KR101744899B1 (ko) 신규 항-tfpi 항체 및 이를 포함하는 조성물
CN117377685A (zh) 具有对Fc受体的增强的亲和力和改善的热稳定性的Fc变体
WO2025077834A1 (en) Anti-il-4ra antibodies and uses thereof
RU2824193C2 (ru) Антигенсвязывающие полипептидные конструкции, содержащие легкие цепи каппа и лямбда, и их применения
KR20250094703A (ko) 향상된 효과기 기능을 갖는 당조작된 Fc 변이체 폴리펩타이드
RU2832921C1 (ru) Модифицированные антигенсвязывающие полипептидные конструкции и их применение
WO2025255558A2 (en) Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
JP2025532504A (ja) 抗ｉｌｔ４抗体及びその医薬的使用
HK40070151A (en) Bispecific antibody and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260804